BioMarin Pharmaceutical Inc.: BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

European Commission Approval Expected Q3 2022 First Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe, Hemophilia

Related Keywords

Germany ,Norway ,Iceland ,Liechtenstein ,Canada ,Bonn ,Nordrhein Westfalen ,Hank Fuchs ,Johannes Oldenburg ,University Clinic In Bonn ,European Commission ,Biomarin Pharmaceutical Inc ,Haemophilia Centre ,Nasdaq ,Replay International Number ,Worldwide Research ,Exchange Commission ,International Number ,European Commission Approval Expected ,Prnewswire Biomarin Pharmaceutical Inc ,Robust Clinical Program ,Committee For Medicinal Products Human Use ,Institute Of Experimental Haematology ,Gene Therapy ,Biomarin Territories Across Europe ,Middle East ,Call Scheduled ,Marin Pharmaceutical ,Medicinal Products ,Human Use ,Professor Johannes Oldenburg ,Experimental Haematology ,Transfusion Medicine ,University Clinic ,Investor Conference Call ,Held Today ,Canada Dial In Number ,Dial In Number ,International Dial In Number ,Biomarin Pharmaceutical ,Quarterly Report ,Biomarin ,Harmaceutical ,Eceives ,Positive ,Thmp ,Opinion ,Europe ,Aloctocogene ,Oxaparvovec ,Gene ,Therapy ,Treat ,Adults ,Evere ,Hemophilia ,